D7139YZ
Brachytherapy Lymphatics, Neck to None with Other Isotope, High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 7 Lymphatic and Hematologic System |
| Operation | 1 Brachytherapy |
| Body Part | 3 Lymphatics, Neck |
| Approach | 9 High Dose Rate (HDR) |
| Device | Y Other Isotope |
| Qualifier | Z None |
Procedure Overview
Brachytherapy of the lymphatic and hematologic system involves placing a radioactive source directly into or adjacent to lymphatic tissue, delivering a concentrated, localized dose while sparing tissue farther from the source. This is less common than external beam treatment for this body system but may be used for localized nodal disease where direct source placement offers better dose control, or in combination with surgery for residual microscopic tumor at a nodal bed.
The radioactive material can be left in place temporarily and removed after a calculated dose is delivered, or in some cases placed permanently as small seeds that decay over time. The approach is chosen when the anatomic target allows safe, direct access for source placement.
Anatomy & Axis Detail
Lymphatics, Neck
Brachytherapy of the cervical lymphatics places a radioactive source directly within or adjacent to involved neck nodal tissue, an approach used when a discrete residual or recurrent nodal deposit persists after external beam treatment or surgery and a concentrated boost dose is needed without re-irradiating the broader neck. Source placement in this region demands precision given the density of critical structures nearby, including the carotid artery, jugular vein, and cranial nerves that traverse the neck, so implants are typically guided by imaging and often performed in conjunction with a surgical procedure to access the nodal bed. This localized technique limits dose to previously treated tissue and skin compared with repeating external beam fields. Documentation should identify the specific nodal site implanted and note any prior neck irradiation.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Other Isotope
Other Isotope is the residual code for a radioactive source used in brachytherapy or systemic radiopharmaceutical therapy that does not correspond to one of the specifically named isotopes in this axis, such as Ir-192, I-125, or Sr-89. It is selected when documentation identifies a distinct radionuclide, or an isotope newly adopted into practice, that lacks its own dedicated value.
Coding & Documentation
Coders confirm brachytherapy by finding documentation of a radioactive source being implanted, inserted, or applied directly at or near the lymphatic target, along with whether the source was temporary or permanent, which determines the correct approach and qualifier values. The radiation oncology or interventional procedure note should specify the isotope, source configuration, and duration of placement.
A frequent mistake is confusing a temporary applicator left in place for a planned removal with a permanent seed implant, which changes both the qualifier and the expected follow-up documentation. Coders should also verify the treated body part matches the nodal region named in the operative note rather than assuming it based on the underlying diagnosis.